Genmab — April 2015
-
BMY har i dag meddelt at de stopper et fase 3 med opdivo. MedWatc skriber at stoffet - et pd-1 hæmmer antistof forventes at omsætte for 5,7 mia usd allerede i 2019. Gamle Medarex ejere må græmme sig endnu engang for den foræring bmy fik for år tilbage - sølle 2 mia usd for Genmabs moder
http://www.natap.org/2007/HCV/103007_01.htm -
...vel at mærke stoppet førtidigt pga god effekt http://finance.yahoo.com/news/bristol-myers-big-drug-study-142312369.html
-
Vejle hospital laver nyt studie med Daratumumab (!). "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " (DARA)https://clinicaltrials.gov/ct2/show/NCT02419118?term=daratumumab&rank=5&submit_fld_opt=
-
The effector mechanisms of daratumumab have been extensively studied in vitro, but the in vivo correlates and key determinants of success or failure when daratumumab is used alone or in combination with lenalidomide for treatment of patients with myeloma have not been clarified.
-
There is potentially a wide spectrum of factors that may influence the quality and duration of response following treatment with daratumumab. The integrity of the patient's immune system may be important. Prior lines of chemotherapy or the myeloma disease itself may impair humural (i.e. complement) or cellular (i.e. ADCC) effector mechanisms that are of importance for the response to daratumumab.
-
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age
-
Hence, our data reinforce the idea of active suppression of antitumor responses by Tregs in MM patients and therefore suggest that targeting patient Tregs before DLI may improve outcome of DLI.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.48.
-
http://www.futuremedicine.com/doi/abs/10.2217/imt.12.116 Mere om Tregs
-
http://www.bloodjournal.org/content/120/12/2352?sso-checked=true Og så lige den sidste. Kunne godt bekymre, at de starter dette studie, idet det kunne være tegn på, at duration ikke er god nok....måske
-
Tror jeg ikke Solsen. Ligner et studie Vejle Sygehus selv har lavet. Hvis Jannsen vitterligt så de problemer havde de sq selv sponsoreret et studie og fået det afviklet.
-
Tror mere det er fordi plessner er ekstremt interesseret i Dara og vil gøre alt for at få mest muligt ud af det. Så tror mere det er ud fra en ren "videnskabelig interesse" at han gør det
-
det er altid positivt med mange ISS studier. Men ofte er det først når produkterne kommer på markedet vi virkelig ser ISS studier
-
Men de må nu gerne komme med den filing.. Det fjerner lige lidt usikkerhed
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind